HOME >> MEDICINE >> NEWS
Experimental drug reverses effects of Fabry disease in mice

Shows promise for related disorders

ANN ARBOR, 12 June 2000 -- A new experimental drug developed at the University of Michigan Medical School is the first treatment shown to reverse the effects in mice of a hereditary, incurable disorder called Fabry (Fah-BRAY) disease, which affects between 6,000 and 10,000 men in the United States.

Results of the study were published in the June 2000 issue of the Journal of Clinical Investigation in an article by James Shayman, M.D., U-M professor of pharmacology and of internal medicine, and colleagues from the U-M and the National Institutes of Health.

Fabry disease is caused by a genetic mutation that prevents production of an enzyme called alpha-galactosidase A, which cells store in tiny globules called lysosomes. The cellular version of a garbage disposal, lysosomes are found in all cells that use enzymes to dissolve specific molecular bonds and digest waste products.

Without alpha-galactosidase A, lysosomes cannot break up one particular type of glycolipid, a long chain of fats and sugars found in cell membranes. As a result, these molecules accumulate within the kidneys, hearts and blood vessels of patients with Fabry disease. Death occurs in early adulthood from renal failure or cardiovascular complications.

For the past 10 years, U-M researchers have been developing and perfecting a family of glycolipid synthesis inhibitors for use in Fabry disease, according to Shayman. "Other researchers tried to replace the missing enzyme, but we concentrated on blocking glycolipid formation by inhibiting a key enzyme the cell needs to produce these molecules. We now have two compounds with high levels of inhibitory activity and no observed toxic side effects."

According to the Journal of Clinical Investigation study, treatment with one of these compounds produced a highly significant reduction in glycolipid levels in kidneys of male mice with Fabry disease. When treated for eight
'"/>

Contact: Sally Pobojewski
pobo@umich.edu
734-647-1844
University of Michigan
11-Jun-2000


Page: 1 2

Related medicine news :

1. St. Jude scientist wins International Society of Experimental Hematology award
2. Experimental drug improves sleep in older patients, Wake Forest Baptist study shows
3. Experimental drug used to treat recurrent ovarian cancer shows promising results
4. Experimental treatment yields new hope for children battling cerebral palsy
5. Experimental drugs show promise in halting brain tumors
6. Experimental drugs reduce neuron death in rats following insulin shock
7. Experimental pill found to improve symptoms in patients with non-small-cell lung cancer
8. Experimental peptides prevent diabetes and halt its progression
9. Experimental testosterone patch shows promise for treating diminished sexual function in surgically menopausal women
10. Clinical Trial Demonstrates Experimental Growth Factor Increases Eligibility For Autologous Stem Cell Transplantation
11. Antibody treatment partially reverses nerve damage in Alzheimer disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... Ocean Springs, Mississippi-based pharmaceutical distributor ... first responders across the United States. Since the start of the global COVID-19 ... medical centers , hospitals , firefighters , and public ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... services to dental groups in the United States, today announced the grand opening ... Beaumont, CA. , Patients will enjoy convenient hours, a comfortable office, and ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang has over ... autism and other developmental disabilities, as well as supporting staff in caring for ... autism, school consultation, and staff development. She joined the company in 2015 as ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... designed to help treat patients with respiratory conditions, including COVID-19, while reducing the ... and oxygen, but it captures exhaled gas and scrubs it free of carbon ...
(Date:8/28/2020)... ... , ... Ziegler, a specialty investment bank, is pleased to ... a tech-enabled behavioral health and well-being solutions provider. , Synchronous Health, a ... (AI) to increase access and quality of behavioral health services, and Adventist Health, ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... 27, 2020 , ... InfoMC, a leading provider of cloud-based ... 2020 System and Organizational Controls (SOC) 1® Type 2 and SOC 2® Type ... These achievements reflect their long-standing commitment to privacy, security, and risk management, while ...
(Date:8/27/2020)... Mich. (PRWEB) , ... August 27, 2020 , ... The flu season is right round ... to get well equipped with all the necessary measures before it begins to harbor its ... also increasing, and it is leaving a huge impact on our lives. Hence it has ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... with Enquire, a leading provider of cloud CRM, marketing automation, and contact center ... partnership will involve the integration of Trella’s performance intelligence data and insights into ...
Breaking Medicine Technology:
Cached News: